Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Research Area(s) / Expertise:
Between the Sessions with Dr Parwani: VESALIUS-CV, KARDINAL, CHIP-BCIS3 & M
Author(s): Purvi Parwani Added: 1 month ago
Dr Purvi Parwani (Loma Linda University Health, US) recaps the standout science from Day 2 of ACC 2026, a day defined by a central theme: challenging long-held assumptions in cardiology. Her summary focuses on what these updates mean for day-to-day clinical practice, from prevention strategies to interventional decision-making.Prevention and Risk ReductionVESALIUS-CV: Showed a 25% reduction in… View more

Intervention

Prevention & Chronic Conditions
Su Down

Author

Research Area(s) / Expertise: Job title: Nurse Consultant Diabetes
Su Down is a Nurse Consultant in Diabetes and is the Clinical Lead for the Intermediate Diabetes community service in Somerset. Her Diabetes nursing career started in 1989, when she set up the diabetes specialist nursing service in Yeovil District Hospital. Su took up the role of Nurse Consultant in 2005 and played a key part in redesigning the diabetes service across the whole of Somerset. She… View more
Smartwatch Data Predicts Heart Failure Exacerbations
Added: 1 month ago Source:  CFR Journal
Consumer wearable devices may offer a scalable method for the daily monitoring of heart failure (HF) symptoms and predicting exacerbations. A new study has detailed how a deep learning model using Apple Watch data can estimate cardiopulmonary fitness and provide early risk discrimination for unplanned healthcare events in patients with HF.¹MethodologyThe Ted Rogers Understanding Exacerbations of… View more

Digital Health

Heart Failure
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Research Area(s) / Expertise: Job title: Professor, Obesity and Stress Hormone Research
Prof Liesbeth van Rossum, MD PhD, is internist-endocrinologist and professor in the field of obesity and stress hormone research at the Erasmus University Medical Center in Rotterdam, Netherlands. Sheis also co-founder of the Obesity Center CGG, an internationally recognised academic centre of obesity management.Prof Van Rossum holds various societal and board positions, amongst the European lead… View more
Dirk Müller-Wieland
Research Area(s) / Expertise: Job title: Professor of Endocrinology, Metabolism and Diabetes
Prof Dirk Müller-Wieland is a specialist in endocrinology and diabetology at University Hospital Aachen, Department of Medical Sciences (Aachen, DE). He leads the Cardiometric Prevention Working Group and the Clinical Study Center. His research and clinical interests focus on gene regulation, lipid metabolism, fat distribution, insulin resistance and cardiovascular risk.He studied medicine in… View more
Nazli Okumus
Research Area(s) / Expertise:
Dr. Nazli Okumus is currently in her third year as a Cardiology Fellow at Allegheny Health Network (AHN) in Pittsburgh, PA, where she is dedicated to advancing her training in interventional cardiology. She successfully completed her residency at Case Western MetroHealth in Cleveland, OH. Her commitments extend to serving as a member of the SCAI Political Action Committee, contributing to the ACC… View more
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Kidney Metabolic
Treatment Options and Continuity of Care in MAFLD
Author(s): Carmen Lara-Romero , Manuel Romero-Gómez Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic